Kymera Therapeutics Inc
KYMR
Market Cap$2.87B
Close$
$-9.72
122.3% downside
Current Fair Value
122.3% downsideOvervalued by 122.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.87 Billion |
|---|---|
| Enterprise Value | $2.89 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.98 |
| Beta | 2.07 |
| Outstanding Shares | 80,146,531 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.68 |
|---|---|
| PEG | -41.87 |
| Price to Sales | - |
| Price to Book Ratio | 4.85 |
| Enterprise Value to Revenue | 49.1 |
| Enterprise Value to EBIT | -10.78 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Kymera Therapeutics Inc
75 employeesKymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted...